Latest News - Clinical Trials

Thursday, February 23, 2017 | Clinical Trials, Medical Studies

ToolGen Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System In Vivo Genome Editing

ToolGen announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo, according to a …

Read the full story

Tuesday, February 21, 2017 | Clinical Trials, Nicox

Nicox Presents NCX 667 Scientific Data at AOPT 2017

Nicox SA announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientif…

Read the full story

Friday, February 17, 2017 | Clinical Trials, Product Releases, Pixium Vision

Pixium Vision Announces First Implantation and Activation of IRIS II in Spain

Pixium Vision announced the first implantation and activation of IRIS II in Spain. This implantation is part of Pixium Vision’s ongoing multicenter clinical trial to assess the performance of IR…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With RVO

Clearside Biomedical announced the enrollment of the first patient in a phase 3 clinical trial (SAPPHIRE) of Zuprata, its proprietary suspension formulation of the corticosteroid triamcinolone acetoni…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Glaukos Corporation

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story

Tuesday, February 14, 2017 | Clinical Trials

Regenxbio Announces IND Active for Phase 1 Trial of RGX-314 to Treat Wet AMD

Regenxbio announced the investigational new drug (IND) application is active for the planned multicenter, open-label, multiple-cohort, dose-escalation phase 1 clinical trial of RGX-314 for the treatme…

Read the full story

Thursday, February 09, 2017 | Clinical Trials

Iconic Therapeutics to Present Phase 2a EMERGE Trial Results

Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced that the res…

Read the full story

Monday, February 06, 2017 | Clinical Trials

Aura Biosciences Receives FDA Clearance of Investigational NDA for Light-Activated AU-011 for the Treatment of Ocular Melanoma

Aura Biosciences announced that the FDA has cleared the investigational new drug application (IND) for the company’s lead program, light-activated AU-011 in ocular melanoma. This active IND enab…

Read the full story

Friday, February 03, 2017 | Clinical Trials, Envisia Therapeutics

Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma

Envisia Therapeutics released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma showing a clinically meaningful reduction in IOP for the en…

Read the full story

Thursday, February 02, 2017 | Clinical Trials, AMD, Genentech

Genentech Completes Patient Enrollment in Two Large Phase 3 Studies for Lampalizumab

Genentech has completed enrollment in two large phase 3 clinical trials, Chroma and Spectri, investigating the efficacy and safety of lampalizumab in reducing the progression of geographic atrophy (GA…

Read the full story

Monday, January 30, 2017 | Clinical Trials

EyeGate Pharma Announces Positive Topline Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

EyeGate Pharmaceuticals announced topline results from the first-in-human pilot trial of its EyeGate Ocular Bandage Gel, the acceleration of reepithelialization of large corneal epithelial defects in …

Read the full story

Friday, January 27, 2017 | Clinical Trials, Acucela

Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease

Acucela announced that on January 25, 2017, the first patient was enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride, in subjects with macular atrophy seco…

Read the full story

Tuesday, January 24, 2017 | Clinical Trials, Genentech

FDA Grants Priority Review for Genentech’s Actemra Supplemental Biologics License Application for Giant Cell Arteritis

Genentech announced that the FDA has accepted the company’s supplemental biologics license application for Actemra (tocilizumab) for the treatment of giant cell arteritis (GCA). The FDA also gra…

Read the full story

Tuesday, January 24, 2017 | Clinical Trials, Nicox

Nicox Provides Clinical and Regulatory Update for NCX 470 for IOP Lowering

Nicox provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide (NO) donating bimatoprost analog being developed for IOP lowering. Nicox held a preinvestigational new dru…

Read the full story

Monday, January 23, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Resubmits NDA for Dextenza for the Treatment of Ocular Pain After Ophthalmic Surgery

Ocular Therapeutix announced that it has resubmitted a new drug application (NDA) to the FDA for Dextenza (dexamethasone insert) 0.4 mg, for the treatment of ocular pain occurring after ophthalmic sur…

Read the full story
Load More